LTBR and neoplasm: The migration of lymphocytes to tumor sites is essential for immune surveillance, and therapies that enhance lymphocyte adhesion and infiltration, such as combinations of anti-VEGFR2 and anti-PD-L1 antibodies, which activate lymphotoxin-beta receptor (LTbR) signaling and lead to the formation of high endothelial venules (HEVs), are being studied for their ability to boost the tumor immune response (94, 95).